31 Aug 2021 18:14
31 August 2021
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Result of GM, TVR and clarification re warrants
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today, all resolutions were passed.
Accordingly, the 88,854,641 new Ordinary shares in respect of the Subscription and fee arrangements, details of which were set out in the Company's announcement of 11 August 2021, will be issued and are expected to be admitted to trading on AIM on 3 September 2021. The remaining 11,145,405 Subscription Shares are expected to be admitted to trading on AIM on or around 1 October 2021.
The results of the proxy voting for the General Meeting are set out below:
Resolution | Total votes For1 | % of votes cast2 | Total Votes Against | % of votes cast2 | Votes Withheld3 |
1 | 120,246,315 | 99.77 | 273,099 | 0.23 | 0 |
2 | 120,459,943 | 99.95 | 59,471 | 0.05 | 0 |
Notes
1. Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution
2. Percentage of votes cast excludes Votes Withheld
3. Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution
Clarification regarding warrants
The following table summarises the warrants that remain in issue. The details in the table below are in accordance with the previous announcements made by the Company, although the dates of two outstanding batches of warrants have been incorrectly reflected in the last annual report due to a typographical error.
Issue Date | Final date of exercise | Exercise price | Number of Warrants |
20-Jul-17 | 19-Jul-22 | 25p | 20,468,687 |
26-Apr-18 | 25-Apr-23 | 70p | 1,000,000 |
31-May-18 | 11-Jun-22 | 50p | 450,000 |
31-Aug-18 | 31-Aug-23 | 100p | 2,617,312 |
07-May-19 | 07-May-24 | 100p | 3,500,000 |
31-Oct-19 | 31-Aug-24 | 100p | 385,000 |
28-Jun-20 | 28-Jun-25 | 50p | 5,000,000 |
Total | 33,420,999 |
Further warrants are due to be granted in respect of the Subscription on the dates falling six months after First Admission and Second Admission, as detailed in the Company's announcement of 11 August 2021.
Total voting rights
The Company's issued share capital as at the date of this announcement comprises 350,334,730 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 350,334,730.
On 3 September 2021, a further 88,854,641 Ordinary Shares will be issued as detailed above. Therefore, from 3 September 2021 the issued share capital of the Company will comprise 439,189,371 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury and therefore the total voting rights in the Company will be 439,189,371. From 3 September 2021, the figure of 439,189,371 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms used in this announcement shall have the same meaning as in the announcement of 11 August 2021 unless otherwise defined herein.
- ENDS -
Notes for editors
Advanced Oncotherapy plc | www.avoplc.com |
Dr. Michael Sinclair, Executive Chairman | Tel: +44 (0) 20 3617 8728 |
Nicolas Serandour, CEO | |
Allenby Capital Limited (Nomad and Joint Broker) | |
Nick Athanas / Liz Kirchner (Corporate Finance) Amrit Nahal / Matt Butlin (Sales and Corporate Broking) | Tel: +44 (0) 20 3328 5656 |
SI Capital Ltd (Joint Broker) | |
Nick Emerson | Tel: +44 (0) 1483 413 500 |
Jon Levinson | Tel: +44 (0) 20 3871 4066 |
FTI Consulting (Financial PR & IR) | advancedoncotherapy@fticonsulting.com |
Simon Conway / Rob Winder | Tel: +44 (0) 20 3727 1000 |
About Advanced Oncotherapy Plc
Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.